Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly low-dose cisplatin vs three-weekly high-dose cisplatin in chemoradiation for sarcopenic LA-HNSCC
2024-514919-10-00Phase 4Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of cisplatin in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Compliance rate to cisplatin regimen (non-CDLT). Planned start Nov 2024; status: authorised.
02
Drugs
cisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-514919-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514919-10-00.